Live Micron Technology Inc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MARINUS PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for MARINUS PHARMACEUTICALS, INC.

MRNS

MARINUS PHARMACEUTICALS, INC.

About MARINUS PHARMACEUTICALS, INC.

Marinus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing neurosteroid-based therapies for rare seizure and neurological disorders. Its flagship product, ZTALMY (ganaxolone), treats seizures associated with Cyclin-dependent Kinase-like 5 Deficiency Disorder (CDD). The company advances clinical programs for other epilepsies, leveraging its expertise in GABAergic modulation, orphan drug designations, and strategic collaborations to address unmet medical needs in neurology.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from MARINUS PHARMACEUTICALS, INC.

1
1
MARINUS PHARMACEUTICALS, INC. Marinus Pharmaceuticals Reports Revenue Growth, Net Loss, and Significant Financial Changes in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments